Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

About Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:REGN
  • CUSIP: 75886F10
  • Web:
  • Market Cap: $50.43886 billion
  • Outstanding Shares: 106,033,000
Average Prices:
  • 50 Day Moving Avg: $493.07
  • 200 Day Moving Avg: $429.52
  • 52 Week Range: $325.35 - $543.55
  • Trailing P/E Ratio: 47.41
  • Foreward P/E Ratio: 32.50
  • P/E Growth: 1.74
Sales & Book Value:
  • Annual Revenue: $5.24 billion
  • Price / Sales: 9.56
  • Book Value: $52.07 per share
  • Price / Book: 9.08
  • EBIDTA: $1.82 billion
  • Net Margins: 22.05%
  • Return on Equity: 25.58%
  • Return on Assets: 16.63%
  • Debt-to-Equity Ratio: 0.13%
  • Current Ratio: 3.75%
  • Quick Ratio: 3.21%
  • Average Volume: 894,994 shs.
  • Beta: 1.66
  • Short Ratio: 2.46
Frequently Asked Questions for Regeneron Pharmaceuticals (NASDAQ:REGN)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its earnings results on Thursday, August, 3rd. The company reported $4.17 EPS for the quarter, beating the consensus estimate of $2.67 by $1.50. The company earned $1.47 billion during the quarter, compared to analysts' expectations of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business's revenue for the quarter was up 21.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.82 EPS. View Regeneron Pharmaceuticals' Earnings History.

Where is Regeneron Pharmaceuticals' stock going? Where will Regeneron Pharmaceuticals' stock price be in 2017?

25 analysts have issued twelve-month target prices for Regeneron Pharmaceuticals' stock. Their predictions range from $345.00 to $598.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $489.18 in the next year. View Analyst Ratings for Regeneron Pharmaceuticals.

What are analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Regeneron’s second-quarter results were impressive as both earnings and sales beat estimates on the back of strong Eylea sales which grabbed additional market share. Regeneron’s key growth driver, Eylea, continues to drive revenues and the company is expanding the drug's label for additional indications. The increase in guidance was also encouraging. The FDA’s approval of Dupixent was a major boost to the company’s portfolio and the company is working to expand its label. A potential approval of the drug in the EU in the second half will further boost sales. Further, the approval of Kevzara (sarilumab) for the treatment of moderately-to-severely active rheumatoid arthritis both in the U.S.and EU has boosted the company’s portfolio. Shares have outperformed the industry so far in 2017. However, sales of Praluent have failed to impress." (8/9/2017)
  • 2. Robert W. Baird analysts commented, "nothing to scoff at," Skorney said in his downgrade note. However, investor expectations for a strong performance has "stretched the valuation beyond what is reasonable" based on the initial launch metrics (see Skorney's track record here).In fact, investor expectation shifted from "high" in late April/May to "extraordinary" today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis' blockbuster therapy, Cosentyx."We believe shares reflect a greater degree of optimism than is warranted," Skorney emphasized. "We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408." (8/8/2017)
  • 3. Cowen and Company analysts commented, "REGN reported Q1:17 U.S." (5/5/2017)
  • 4. BMO Capital Markets analysts commented, "We raise our price target to $412 but maintain our Market Perform rating on REGN following Dupixent approval in adult atopic dermatitis. While the approval was widely expected and reflects the strength of Dupixent's clinical profile, we believe the $37k gross price (~$30k net) is higher than expected (BMO: ~$25k prior) and could lead to even more aggressive management by payors. Thus, while we have updated our model to reflect Dupixent's actual price, we have slowed our ramp on our expectation for increased access restrictions given the therapy's high price." (3/28/2017)

Who are some of Regeneron Pharmaceuticals' key competitors?

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:

  • P. Roy Vagelos M.D., Chairman of the Board
  • Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director
  • Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance
  • Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply
  • Neil Stahl Ph.D., Executive Vice President - Research and Development
  • Robert J. Terifay, Executive Vice President - Commercial
  • Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary
  • Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation
  • Peter Powchik M.D., Senior Vice President - Clinical Development
  • George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director

Who owns Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (6.67%), Capital World Investors (6.54%), BlackRock Inc. (5.86%), Vanguard Group Inc. (4.99%), State Street Corp (3.10%) and Artisan Partners Limited Partnership (1.86%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Douglas S Mccorkle, George Yancopoulos, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Who sold Regeneron Pharmaceuticals stock? Who is selling Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Southpoint Capital Advisors LP, Capital World Investors, Bank of New York Mellon Corp, State Street Corp, Manning & Napier Advisors LLC, BB Biotech AG, Ameriprise Financial Inc. and Rockefeller Financial Services Inc.. Company insiders that have sold Regeneron Pharmaceuticals stock in the last year include Arthur F Ryan, Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Robert J Terifay. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Who bought Regeneron Pharmaceuticals stock? Who is buying Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Jennison Associates LLC, FMR LLC, TIAA CREF Investment Management LLC, PointState Capital LP, Vanguard Group Inc., Teachers Advisors LLC and Polen Capital Management LLC. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy Regeneron Pharmaceuticals stock?

Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $472.56.

MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  938 (Vote Outperform)
Underperform Votes:  706 (Vote Underperform)
Total Votes:  1,644
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 14 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.36)
Consensus Price Target: $489.18 (3.52% upside)

Analysts' Ratings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/15/2017J P Morgan Chase & CoReiterated RatingHoldLowView Rating Details
8/15/2017Leerink SwannReiterated RatingOutperform -> Positive$580.00 -> $552.00LowView Rating Details
8/14/2017Canaccord GenuitySet Price TargetBuy$522.00LowView Rating Details
8/9/2017Jefferies Group LLCReiterated RatingHold$418.00 -> $471.00LowView Rating Details
8/9/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$469.00 -> $472.00LowView Rating Details
8/8/2017Robert W. BairdDowngradeNeutral -> Underperform$408.00LowView Rating Details
8/4/2017Citigroup Inc.Boost Price TargetBuy$555.00 -> $575.00LowView Rating Details
8/3/2017BMO Capital MarketsSet Price TargetHold$491.00LowView Rating Details
8/1/2017Piper Jaffray CompaniesReiterated RatingOverweight$557.00HighView Rating Details
7/22/2017Barclays PLCReiterated RatingEqual Weight$400.00 -> $450.00LowView Rating Details
7/21/2017Bank of America CorporationReiterated RatingBuy$589.00 -> $593.00LowView Rating Details
7/14/2017Credit Suisse GroupDowngradeHold$485.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual Weight$405.00 -> $450.00MediumView Rating Details
6/30/2017BTIG ResearchReiterated RatingBuy -> Buy$480.00 -> $540.00HighView Rating Details
6/26/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$410.00 -> $480.00LowView Rating Details
6/22/2017Raymond James Financial, Inc.Reiterated RatingOutperform$475.00 -> $547.00MediumView Rating Details
6/14/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldLowView Rating Details
5/15/2017Cowen and CompanyReiterated RatingHold$380.00LowView Rating Details
3/17/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
1/10/2017Wells Fargo & CompanyReiterated RatingMarket PerformN/AView Rating Details
1/8/2017Evercore ISISet Price TargetHold$421.00N/AView Rating Details
1/6/2017Royal Bank Of CanadaReiterated RatingOutperform$626.00 -> $598.00N/AView Rating Details
1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 -> $345.00N/AView Rating Details
12/28/2016ArgusReiterated RatingBuy$450.00N/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$520.00N/AView Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$489.00N/AView Rating Details
3/17/2016SunTrust Banks, Inc.Lower Price TargetNeutral$450.00 -> $410.00N/AView Rating Details
3/15/2016GabelliInitiated CoverageBuy$574.00N/AView Rating Details
(Data available from 8/16/2015 forward)


Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Earnings by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Earnings History by Quarter for Regeneron Pharmaceuticals (NASDAQ REGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017$2.67$4.17$1.36 billion$1.47 billionViewListenView Earnings Details
5/4/2017Q1 2017$2.50$2.92$1.30 billion$1.32 billionViewListenView Earnings Details
2/9/2017Q4 2016$3.03$3.04$1.30 billion$1.23 billionViewListenView Earnings Details
11/4/2016Q316$2.73$3.13$1.29 billion$1.22 billionViewN/AView Earnings Details
8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/AView Earnings Details
5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/AView Earnings Details
2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListenView Earnings Details
11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListenView Earnings Details
8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListenView Earnings Details
5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/AView Earnings Details
2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/AView Earnings Details
11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/AView Earnings Details
8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/AView Earnings Details
5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/AView Earnings Details
11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/AView Earnings Details
5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/AView Earnings Details
2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/AView Earnings Details
10/24/2012$1.14$1.89ViewN/AView Earnings Details
7/25/2012$0.45$0.90ViewN/AView Earnings Details
4/26/2012($0.33)$0.37ViewN/AView Earnings Details
2/13/2012($0.60)($0.37)ViewN/AView Earnings Details
7/28/2011($0.40)($0.69)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)
Current Year EPS Consensus Estimate: $13.81 EPS
Next Year EPS Consensus Estimate: $14.54 EPS


Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 67.16%
Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/8/2017Robert E LandrySVPSell526$472.19$248,371.94View SEC Filing  
6/22/2017Michael S AbermanSVPSell2,269$532.42$1,208,060.98View SEC Filing  
6/22/2017Neil StahlEVPSell8,306$532.55$4,423,360.30View SEC Filing  
6/20/2017Michael S BrownDirectorSell3,000$500.00$1,500,000.00View SEC Filing  
6/16/2017Robert J TerifayEVPSell21,147$468.19$9,900,813.93View SEC Filing  
6/15/2017Neil StahlEVPSell8,567$468.45$4,013,211.15View SEC Filing  
6/9/2017Joseph L GoldsteinDirectorSell1,000$482.55$482,550.00View SEC Filing  
6/2/2017Neil StahlEVPSell2,812$479.49$1,348,325.88View SEC Filing  
6/2/2017SanofiMajor ShareholderBuy136,050$478.17$65,055,028.50View SEC Filing  
5/25/2017P Roy VagelosChairmanSell9,295$458.14$4,258,411.30View SEC Filing  
5/12/2017Michael S BrownDirectorSell3,000$450.00$1,350,000.00View SEC Filing  
3/29/2017Michael S BrownDirectorSell1,000$400.00$400,000.00View SEC Filing  
1/11/2017SanofiMajor ShareholderBuy87,298$369.71$32,274,943.58View SEC Filing  
12/12/2016Charles A BakerDirectorSell3,000$392.02$1,176,060.00View SEC Filing  
11/15/2016Arthur F RyanDirectorSell2,000$429.34$858,680.00View SEC Filing  
11/14/2016Joseph L GoldsteinDirectorSell2,125$450.00$956,250.00View SEC Filing  
7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.00View SEC Filing  
6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66View SEC Filing  
5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.00View SEC Filing  
5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.01View SEC Filing  
4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.00View SEC Filing  
3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.00View SEC Filing  
2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22View SEC Filing  
1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52View SEC Filing  
12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.32View SEC Filing  
12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00View SEC Filing  
12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44View SEC Filing  
11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00View SEC Filing  
11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55View SEC Filing  
11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.45View SEC Filing  
11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98View SEC Filing  
11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28View SEC Filing  
10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98View SEC Filing  
9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03View SEC Filing  
9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00View SEC Filing  
9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.00View SEC Filing  
8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30View SEC Filing  
7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00View SEC Filing  
6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00View SEC Filing  
5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81View SEC Filing  
5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40View SEC Filing  
5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00View SEC Filing  
5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00View SEC Filing  
5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00View SEC Filing  
3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00View SEC Filing  
3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57View SEC Filing  
3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00View SEC Filing  
3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93View SEC Filing  
3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00View SEC Filing  
2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00View SEC Filing  
2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00View SEC Filing  
2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91View SEC Filing  
2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42View SEC Filing  
2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00View SEC Filing  
2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32View SEC Filing  
1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00View SEC Filing  
1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76View SEC Filing  
12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39View SEC Filing  
12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90View SEC Filing  
11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00View SEC Filing  
11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51View SEC Filing  
11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98View SEC Filing  
11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50View SEC Filing  
11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00View SEC Filing  
11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10View SEC Filing  
10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12View SEC Filing  
10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00View SEC Filing  
10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60View SEC Filing  
9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42View SEC Filing  
9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80View SEC Filing  
9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96View SEC Filing  
8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00View SEC Filing  
8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00View SEC Filing  
8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00View SEC Filing  
8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00View SEC Filing  
8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00View SEC Filing  
8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28View SEC Filing  
8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16View SEC Filing  
8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92View SEC Filing  
8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60View SEC Filing  
8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22View SEC Filing  
8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00View SEC Filing  
7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00View SEC Filing  
7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00View SEC Filing  
7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00View SEC Filing  
7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00View SEC Filing  
7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00View SEC Filing  
7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00View SEC Filing  
6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00View SEC Filing  
5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.17View SEC Filing  
5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04View SEC Filing  
3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85View SEC Filing  
3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45View SEC Filing  
3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.00View SEC Filing  
3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95View SEC Filing  
3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30View SEC Filing  
3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99View SEC Filing  
3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.00View SEC Filing  
3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06View SEC Filing  
3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55View SEC Filing  
3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12View SEC Filing  
3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44View SEC Filing  
3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28View SEC Filing  
2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.00View SEC Filing  
2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00View SEC Filing  
2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.05View SEC Filing  
2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00View SEC Filing  
2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.58View SEC Filing  
2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.00View SEC Filing  
2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.16View SEC Filing  
2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.20View SEC Filing  
2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.84View SEC Filing  
2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.71View SEC Filing  
2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.00View SEC Filing  
2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00View SEC Filing  
2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00View SEC Filing  
2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.50View SEC Filing  
2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58View SEC Filing  
2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68View SEC Filing  
2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16View SEC Filing  
1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00View SEC Filing  
1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00View SEC Filing  
1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00View SEC Filing  
1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.36View SEC Filing  
12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.93View SEC Filing  
11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00View SEC Filing  
11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.00View SEC Filing  
9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.83View SEC Filing  
9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.16View SEC Filing  
9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.09View SEC Filing  
9/18/2013William RobertsVPSell15,000$304.00$4,560,000.00View SEC Filing  
9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00View SEC Filing  
8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.00View SEC Filing  
6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00View SEC Filing  
5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00View SEC Filing  
5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00View SEC Filing  
5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90View SEC Filing  
5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00View SEC Filing  
5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69View SEC Filing  
5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44View SEC Filing  
5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00View SEC Filing  
5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13View SEC Filing  
5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70View SEC Filing  
11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66View SEC Filing  
11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00View SEC Filing  
11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00View SEC Filing  
11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00View SEC Filing  
9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00View SEC Filing  
8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Regeneron Pharmaceuticals (NASDAQ:REGN)
Latest Headlines for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateHeadline logoRegeneron Pharmaceuticals, Inc. – Value Analysis (NASDAQ:REGN) : August 15, 2017 - August 16 at 7:14 AM logoLeerink Swann Reiterates "Positive" Rating for Regeneron Pharmaceuticals, Inc. (REGN) - August 15 at 5:32 PM logoJ P Morgan Chase & Co Reaffirms Hold Rating for Regeneron Pharmaceuticals, Inc. (REGN) - August 15 at 2:12 PM logoFDA Lifts Hold On CVM's Study, FATE On Track, REGN, OPHT, ZYNE All Flunk Trials - Nasdaq - August 15 at 6:37 AM logoRegeneron To Discontinue Development Of Suptavumab For RSV ... - Nasdaq - August 15 at 6:37 AM logoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT Set at $522.00 by Canaccord Genuity - August 14 at 7:20 PM logoIHS Markit Score downgrades Regeneron Pharmaceuticals Inc to 29 out of 100, ranking positively in only one out of three available IHS Markit categories. - August 12 at 7:21 AM logoSee what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. - August 11 at 8:01 AM logoRobert E. Landry Sells 526 Shares of Regeneron Pharmaceuticals, Inc. (REGN) Stock - August 9 at 9:04 PM logoRegeneron Pharmaceuticals' (REGN) Hold Rating Reaffirmed at Jefferies Group LLC - August 9 at 11:26 AM logoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Downgraded by Robert W. Baird to Underperform - August 8 at 6:26 PM logoReassessing Regeneron - Seeking Alpha - August 8 at 6:36 AM logoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT Raised to $575.00 at Citigroup Inc. - August 7 at 12:20 AM logoRegeneron Pharmaceuticals' (NASDAQ:REGN) Buy Rating Reaffirmed at UBS AG - August 6 at 11:00 PM logoRegeneron beats profit view, to end antibody deal with Sanofi - August 5 at 6:37 AM logoWe're in the business of being really innovative: Regener... - August 5 at 6:36 AM logoVertex Pharmaceuticals vs. Regeneron Pharmaceuticals: Which Company Reported Better Earnings - August 5 at 6:36 AM logoRegeneron Pharmaceuticals (REGN) Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 4 at 7:33 AM logoEdited Transcript of REGN earnings conference call or presentation 3-Aug-17 12:30pm GMT - August 4 at 7:33 AM logoRegeneron beats Street 2Q forecasts - August 4 at 7:33 AM logoRegeneron Pharmaceuticals, Inc. (REGN) Posts Quarterly Earnings Results, Beats Estimates By $1.00 EPS - August 3 at 8:52 PM logoRegeneron Pharmaceuticals, Inc. (REGN) Given a $522.00 Price Target at Canaccord Genuity - August 3 at 7:20 PM logo$1.36 Billion in Sales Expected for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) This Quarter - August 3 at 7:28 AM logoFDA panel votes against approval of J&J arthritis drug - Reuters - August 2 at 8:53 PM logoEarnings Preview: What To Expect From Regeneron Pharmaceuticals On Thursday - August 2 at 3:50 PM logoRegeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : August 2, 2017 - August 2 at 3:50 PM logoExpectations For Regeneron No Longer Realistic; Analyst Downgrades - August 2 at 7:07 AM logoEylea Could Continue to Generate High Revenue - August 2 at 7:07 AM logoKevzara Launch Could Boost Regeneron’s Revenue Growth - August 2 at 7:07 AM logoDupixent Could Substantially Drive Regeneron’s Growth - August 2 at 7:07 AM logo$2.67 EPS Expected for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) This Quarter - August 2 at 12:14 AM logoBUZZ-US STOCKS ON THE MOVE- Charter, Dynavax, Boeing, CDI Corp,Regeneron - Nasdaq - August 1 at 5:40 AM logoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rating Reaffirmed by BMO Capital Markets - July 31 at 9:22 PM logoCanaccord Genuity Analysts Give Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) a $522.00 Price Target - July 30 at 4:34 PM logoIn win for Merus, court rules Regeneron obtained patent through deception - July 29 at 6:41 AM logoAgree To Buy Regeneron Pharmaceuticals At $370, Earn 6.4% Using Options - July 29 at 6:41 AM logoRegeneron Pharmaceuticals, Inc. (REGN) Receives Consensus Recommendation of "Hold" from Brokerages - July 28 at 8:45 PM logoU.S. Court of Appeals for the Federal Circuit Affirms Merus' Inequitable Conduct Claim Against Regeneron - July 28 at 8:32 AM logoOpinion: Ignore the Obamacare fight in Congress and buy these 5 health-care stocks - MarketWatch - July 27 at 6:47 AM logoHealth-care fund managers say a spike in drugs and devices will produce big returns - MarketWatch - July 26 at 6:45 AM logoPro-Trader Daily: Featured Company News - Regeneron and Sanofi Receive Positive CHMP's Opinion for Dupixent(R) - July 24 at 5:55 PM logoFeatured Company News - Regeneron and Sanofi Receive Positive CHMP's Opinion for Dupixent(R) - July 24 at 5:55 PM logoRegeneron Pharmaceuticals, Inc. (REGN) Given "Equal Weight" Rating at Barclays PLC - July 22 at 6:28 PM logoTesla Moves Up In Market Cap Rank, Passing Regeneron Pharmaceuticals - Nasdaq - July 22 at 8:09 AM logoSanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis - July 22 at 8:09 AM logoRegeneron Pharmaceuticals' (NASDAQ:REGN) "Market Perform" Rating Reaffirmed at BMO Capital Markets - July 21 at 1:44 PM logoRegeneron Pharmaceuticals, Inc. (REGN) Given Buy Rating at Bank of America Corporation - July 21 at 12:30 PM logo3 Big Stock Charts for Thursday: Tripadvisor Inc (TRIP), Regeneron Pharmaceuticals Inc (REGN) and Lam Research ... - - July 21 at 6:37 AM logoStocks End Tightly Mixed; These 4 Drugmakers Prop Nasdaq, S&P 500 - July 21 at 6:37 AM logo3 Big Stock Charts for Thursday: Tripadvisor Inc (TRIP), Regeneron Pharmaceuticals Inc (REGN) and Lam Research Corporation (LRCX) - July 20 at 12:30 PM



Regeneron Pharmaceuticals (REGN) Chart for Wednesday, August, 16, 2017

This page was last updated on 8/16/2017 by Staff